This post was originally published on this site A Phase 1/2 trial assessing Oncternal Therapeutics‘ cirmtuzumab plus Imbruvica (ibrutinib) for the treatment of B-cell cancers is opening a Phase 1b extension part to continue studying the combination in people with mantle cell lymphoma (MCL), the company announced. The expansion was based on positive interim results from…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Celebs in Parody Video Urge Support for Movember to Raise Prostate Cancer Awareness
This post was originally published on this site In a lighthearted twist on a serious goal of raising awareness and funds for prostate cancer, the Movember Foundation is again encouraging gents to join glitterati in celebrating the moustache. The annual event is called Movember, a blending of the Australian-English “mo” for moustache with “November,” the month…
Lynparza-Avastin First-Line Maintenance Therapy Delays Cancer Progression in Advanced OC, Phase 3 Study Shows
This post was originally published on this site Adding Lynparza (olaparib) to Avastin (bevacizumab) as a first-line maintenance treatment significantly delayed disease progression in women with advanced ovarian cancer — regardless of BRCA mutation status — interim data from a Phase 3 study show. This maintenance therapy was given after partial or complete response to first-line platinum-based chemotherapy. The…
CARsgen’s CT053 Receives RMAT Status from FDA for Multiple Myeloma Treatment
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted its Regenerative Medicine Advanced Therapy (RMAT) designation to the investigational therapy CT053 for the treatment of relapsed or refractory multiple myeloma. The RMAT designation is given to regenerative therapies intended to treat, modify, reverse, or cure a serious…
European Commission Approves Bavencio-Inlyta for First-line Treatment of Advanced Kidney Cancer
This post was originally published on this site The European Commission (EC) has approved a combination regimen of Bavencio (avelumab) injections plus Inlyta (axitinib) tablets for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC), the most common type of kidney cancer. The combination can be used in patients regardless of their predicted…
Seattle Genetics’ Tucatinib Extends Survival Outcomes in Metastatic HER2-positive Breast Cancer Patients, Phase 2 Trial Shows
This post was originally published on this site People with HER-positive advanced breast cancer who received multiple HER-targeted therapies have significantly better survival outcomes — including overall survival and survival without disease progression — when given a combination of Seattle Genetics‘ tucatinib plus standard trastuzumab and Xeloda (capecitabine), results from a Phase 2 trial show.…
Copiktra Superior to Arzerra for CLL/SLL Patients with Prior Therapies, Data Suggest
This post was originally published on this site Treatment with Copiktra (duvelisib) doubles response rates compared with Arzerra (ofatumumab), and significantly extends the time until disease progression or death in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two previous therapies, a Phase 3 trial revealed. The…
Targeted Radiation (SBRT) Can Control Prostate Cancer That Has Spread Slightly, Trial Results Suggest
This post was originally published on this site Stereotactic body radiation therapy (SBRT) — a form of targeted, high-dose radiation therapy — significantly extends the time without detectable disease progression when given to prostate cancer patients with limited metastatic lesions, data from a Phase 2 trial show. These findings were presented at the recent 2019 American…
Trabectedin, Bevacizumab, Platinum Chemotherapy Combo May Work, But Safety a Concern, Study Finds
This post was originally published on this site Women with ovarian cancer who are partially sensitive to platinum-based chemotherapy may benefit from a new combination therapy — but safety concerns need to be addressed first, a study suggests. The new study proposes a combination of trabectedin and bevacizumab with platinum-based chemotherapy for these patients, whose disease…
I-Mab Expands its Ongoing Myeloma Clinical Trials of MOR202 to China
This post was originally published on this site I-Mab Biopharma is expanding to mainland China its ongoing clinical studies assessing MorphoSys‘ investigational antibody therapy MOR202 (TJ202) as treatment for people with multiple myeloma, the company announced. The decision comes after an Investigational New Drug clearance issued by China’s National Medical Products Administration (NMPA). The ongoing…
Unusual Case of Tears in Heart Blood Vessels Found in Cardiac Sarcoidosis Patient
This post was originally published on this site Tears in blood vessels of the heart can occur in people with cardiac sarcoidosis, a case report found, although the incidence of this complication appears to be low. The report, “Spontaneous coronary artery dissection in cardiac sarcoidosis,” was published in Oxford Medical Case Reports. Spontaneous coronary artery dissection…
Keytruda Survival Benefits Similar to Chemo for Relapsed Mesothelioma, Phase 3 Trial Finds
This post was originally published on this site Treatment with the immunotherapy Keytruda (pembrolizumab) appears to be as effective as conventional chemotherapy for treating malignant pleural mesothelioma patients who relapse after one course of platinum-based chemotherapy, data from a Phase 3 trial show. Although more of these advanced cancer patients responded to Keytruda than to…